GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$1.80
0.15 (9.28%)
▲
5d:
+4.23%
30d:
+24.36%
90d:
-12.47%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GRI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GRI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $1.80, which is considered extended relative to its 30-day fair value range of $1.41 to $1.78.
Technical Outlook: Technically, GRI is in a strong downtrend. Immediate support is located at $1.61, while resistance sits at $2.55. The stock is showing strong short-term momentum, up 9.3% recently.
Market Sentiment: GRI scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+1172.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is in a strong downtrend. Immediate support is located at $1.61, while resistance sits at $2.55. The stock is showing strong short-term momentum, up 9.3% recently.
Market Sentiment: GRI scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+1172.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.41 -
$1.78
Company Quality Score
28/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: Strong upward momentum (+9.3%)
- BULLISH: Trading 1172.7% below Wall St target ($21.00)
- WARNING: Composite score 28/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.78
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.61
Resistance Level
$2.55
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.65
Wall Street Target
$21.00
(+1172.7%)
Share & Embed Analysis
Last updated: August 24, 2026 2:32 PM ET
Data refreshes hourly during market hours. Next update: 3:32 PM
Data refreshes hourly during market hours. Next update: 3:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 48 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 33 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 41 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
